LifeSci Capital Initiates Coverage of Biotech Exchange Traded Funds (ETFs)

Intends to Provide Ongoing Coverage of the Biotech ETF Sector; Report Available here: http://www.lifescicapital.com/equity-research/etf-coverage/

NEW YORK, NY / ACCESSWIRE / March 31, 2015 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of the biotechnology exchange trade fund (ETF) sector. ETFs included in our sector analysis include the iShares Nasdaq Biotechnology Index Fund (IBB), the First Trust NYSE Arca Biotech ETF (FBT), the SPDR S&P Biotech ETF (XBI), the Market Vectors Biotech ETF (BBH), the PowerShares Dynamic Biotech & Genome ETF (PBE), the BioShares Biotechnology Clinical Trials Index Fund (NASDAQ:BBC), and the BioShares Biotechnology Products Fund (NASDAQ:BBP). LifeSci Capital intends to provide ongoing research coverage of these ETFs, including tracking relevant catalysts for the ETF component companies.

“With the continued strength of the biotech sector, biotechnology ETFs have become increasingly popular investment vehicles,” said Jerry Isaacson, Ph.D., LifeSci Capital’s Director of Research. “Considering this popularity, and the introduction of innovate new biotech ETFs, our research will strive to provide investors coverage of the funds themselves, major topics in the space, and important clinical and regulatory events.”

In the ETF Sector Initiation Report LifeSci Capital explains the composition of each biotech ETF and the differences in investment methodology. We explore the different types of companies in each ETF and discuss the type of investment strategy that each fund offers. The current biotech ETFs provide a variety of different weighting and selection strategies, and we examine the particular aspects of each.

LifeSci Index Partners, an affiliate of LifeSci Capital, is the sub-adviser to the BioShares ETFs.

Dr. Isaacson’s full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on the Biotech ETF Sector as developments occur.

The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients’ businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company’s website, www.lifescicapital.com.

Analyst Contact:

Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com

SOURCE: LifeSci Capital, LLC

ReleaseID: 427359